The PEPperCHIP® SARS-CoV-2 Proteome Microarray covers the entire SARS-CoV-2 viral proteome (including mutations of the B1.1.7, 501.V2, B1.1.28 and P.1 Manaus variants, and all spike protein mutations of the Alpha, Beta, Gamma, Delta, Delta Plus and Omicron variants of concern) converted into highly overlapping peptides. The microarray chip contains 5,347 linear 15-mer peptides with a 13-mer overlap (shift 2) in duplicates, as well as HA and polio positive control peptides.
Identify, profile and compare SARS-CoV-2 specific IgG, IgA, and IgM responses in patient or animal sera for vaccine development. Screen viral antigens to find and characterize immunodominant epitopes for in-vitro diagnostics research. The microarray can be used for proteome-wide epitope mapping, serum screening or biomarker discovery.
The PEPperCHIP® SARS-CoV-2 Proteome Microarray can be used for the following applications
• | Screening and serological profile analysis of IgA, IgG, and IgM responses on the epitope level for in-vitro test development. |
• | Immune monitoring of antibody responses in SARS-CoV-2 vaccination trials. |
• | Epitope analysis of prognostic or neutralizing antibodies in patient sera for vaccine optimization and development. |
• | Epitope identification and characterization of anti-SARS-CoV-2 antibodies. |
See also
• | Infographic: Proteome-wide IgA and IgG epitope mapping of COVID-19 patient sera |
• | Poster: Epitope signatures in COVID-19 patients with mild and severe disease |
Microarray information
• | Microarray content: full proteome of SARS-CoV-2 derived from the virus isolate sequence under GenBank ID: MN908947.3 (including 49 mutations of the B1.1.7, 501.V2, B1.1.28 and P.1 Manaus variants and all spike protein mutations of the Alpha, Beta, Gamma, Delta, Delta Plus and Omicron variants of concern) |
• | Peptide length and overlap: 15 aa peptides with peptide-peptide overlap of 13 aa (shift 2) |
• | Number of peptides / spots: 5,347 / 10,694 (peptides printed in duplicate) |
• | Positive control: HA (YPYDVPDYAG) and polio (KEVPALTAVETGAT) control peptides |
• | Size and format: 3'' x 1'', 75.4 mm x 25.0 mm x 1.0 mm, containing 1 array copy per chip |
• | Accessories: compatible with 3/1 well PEPperCHIP® Incubation Tray |
Sample information
• | Can be assayed with at least 20 µL serum/plasma or 10-20 µg/mL purified antibody. |
Estimated delivery time
• | 1-4 weeks for chip and optional add-on accessories |
• | 6-8 weeks when requested with PEPperMAP® Services. |
Documentation
• | PEPperCHIP® SARS-CoV-2 Proteome Microarray Material Data Sheet [download pdf] |
• | PEPperCHIP® SARS-CoV-2 Proteome Microarray Peptide Map [download xlsx] |
Learn how to perform the assay
• | PEPperCHIP® Immunoassay Protocol [download pdf] [watch video] |
• | PEPperCHIP® Immunoassay Quickstart Guide [download pdf] |
Steps | Materials and equipment | We recommend |
Immunoassay | Incubation tray | PEPperCHIP® Incubation Tray* |
Orbital shaker | - | |
Blocking reagents | BSA, or Rockland Blocking Buffer* | |
Control antibodies | PEPperCHIP® Control Antibodies | |
Buffers | PBS, Tween 20 | |
Labelled secondary antibodies | Rockland secondary antibodies* | |
Data acquisition | Microarray scanner | Innopsys InnoScan® 710/710-IR* |
Data analysis | Fluorescence spot intensity quantification software | MAPIX Analyzer by Innopsys |
Spreadsheet software | - |
*used in-house by PEPperPRINT
Longitudinal Development of Antibody Responses in COVID-19 Patients of Different Severity with ELISA, Peptide, and Glycan Arrays: An Immunological Case Series.
Jasmin Heidepriem, Christine Dahlke, Robin Kobbe, René Santer, Till Koch, Anahita Fathi, Bruna M. S. Seco, et al. Pathogens 10, Nr. 4 (April 2021): 438.
doi.org/10.3390/pathogens10040438.
Immunodominant B Cell Epitope in SARS-CoV-2 RBD Comprises a B.1.351 and P.1 Mutation Hotspot: Implications for Viral Spread and Antibody Escape.
Keity Souza Santos, Jamille Ramos Oliveira, Rafael Rahal G. Machado, Helen Andrade Arcuri, Jhosiene Yukari Magawa, Isabela Pazotti Daher, Alysson Henrique Urbanski, et al. MedRxiv, 12. March 2021, 2021.03.11.21253399. doi.org/10.1101/2021.03.11.21253399.
SARS-CoV-2 proteome-wide analysis revealed significant epitope signatures in COVID-19 patients.
Tatjana Schwarz, Kirsten Heiss, Yuvaraj Mahendran, Fiordiligie Casilag, Florian Kurth, Leif Sander, Clemens-Martin Wendtner, Manuela A. Hoechstetter, Marcel A. Müller, Renate Sekul, Christian Drosten, Volker Stadler and Victor M. Corman. Front. Immunol. [https://www.frontiersin.org/articles/10.3389/fimmu.2021.629185/abstract]
SARS-CoV-2 Spike Protein Arrested in the Closed State Induces Potent Neutralizing Responses.
George W. Carnell, Katarzyna A. Ciazynska, David A. Wells, Xiaoli Xiong, Ernest T. Aguinam, Stephen H. McLaughlin, Donna Mallery. Preprint. Immunology, 14. January 2021. [doi.org/10.1101/2021.01.14.426695]
SARS-CoV-2 Epitope Mapping on Microarrays Highlights Strong Immune-Response to N Protein Region.
Angelo Musicò, Roberto Frigerio, Alessandro Mussida, Luisa Barzon, Alessandro Sinigaglia, Silvia Riccetti, Federico Gobbi. Vaccines 9, Nr. 1 (11. January 2021): 35. [doi.org/10.3390/vaccines9010035]
Recent Advances in the Diagnosis of COVID-19: A Bird’s Eye View.
Bhawna Sharma, Mohd FardeenHusain Shahanshah, Sanjay Gupta, and Vandana Gupta. Expert Review of Molecular Diagnostics, 10. January 2021, 14737159.2021.1874354. [doi.org/10.1080/14737159.2021.1874354]
Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping.
Yan Lu, Yajun Wang, Zhen Zhang, Jingliang Huang, Meicun Yao, Guobin Huang, Yuanyuan Ge, et al. Published by Juraj Ivanyi. Journal of Immunology Research 2020 (16. October 2020): 1–8. [doi.org/10.1155/2020/9465398]
Rapid Response to Pandemic Threats: Immunogenic Epitope Detection of Pandemic Pathogens for Diagnostics and Vaccine Development Using Peptide Microarrays.
Kirsten Heiss, Jasmin Heidepriem, Nico Fischer, Laura K Weber, Christine Dahlke, Thomas Jaenisch, und Felix F Loeffler. Journal of Proteome Research, 5. September 2020 [doi.org/10.1021/acs.jproteome.0c00484]
Molecular and Serological Tests for COVID-19. A Comparative Review of SARS-CoV-2 Coronavirus Laboratory and Point-of-Care Diagnostics.
Kubina, Robert, und Arkadiusz Dziedzic. Diagnostics 10, Nr. 6 (26. June 2020): 434. [doi.org/10.3390/diagnostics10060434]
Distinct Early IgA Profile May Determine Severity of COVID-19 Symptoms: An Immunological Case Series.
Dahlke, Christine, Jasmin Heidepriem, Robin Kobbe, Rene Santer, Till Koch, Anahita Fathi, My L. Ly, et al. Preprint. Infectious Diseases (except HIV/AIDS), April 17, 2020 [doi.org/10.1101/2020.04.14.20059733]
Identify, profile, and compare SARS-CoV-2-specific IgG, IgA, and IgM responses in patient or animal sera for vaccine development, or screen viral antigens to find and characterize immunodominant epitopes for in-vitro diagnostics research.
475.00 EUR
Excl. tax and shipping costs.
